证券代码：301371 证券简称：敷尔佳 哈尔滨敷尔佳科技股份有限公司 投资者关系活动记录表 编号：2026-005 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 嘉实基金管理有限公司 靳雨鑫 国海证券股份有限公司 李宇宸 卢世伟 时间 2026 年 3 月 4 日 15：30-16：20 地点 电话会议 上市公司接待 人员姓名 邓百娇女士 董事、董事会秘书 吴 弘先生 证券事务代表 齐鑫鑫女士 投资者关系管理 IR 投资者关系活 动主要内容介 绍 Q1、本次三八节公司线上销售情况如何？ A：目前三八节活动还未结束，具体销售数据还不确定， 公司按照惯例积极跟随各大电商平台活动节奏，在节日活动前 进行预热推广，进一步提高公司品牌知名度与产品曝光度，希 望本次三八节活动能够取得优异的销售成绩，为公司的业绩增 长做出积极贡献。 Q2、公司除面膜外，后续在次抛、水乳、精华上有什么 新品的规划？ A：对于以上剂型，公司在今年上新计划（含旧品升级） 中都有规划，除贴片类产品外，还覆盖水、乳 ...

2 编号：2026-003 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 工银瑞信基金管理有限公司 秦聪 马丁 国海证券股份有限公司 李宇宸 时间 2026 年 2 月 27 日 15：00-15：40 地点 电话会议 上市公司接待 人员姓名 邓百娇女士 董事、董事会秘书 吴 弘先生 证券事务代表 齐鑫鑫女士 投资者关系管理 IR 投资者关系活 动主要内容介 绍 Q1、请简要介绍一下公司的产品结构情况。 A：目前公司产品主要分为医疗器械类产品与功能性护肤 品两大板块，从剂型上主要分贴片类与非贴片类，非贴片类涵 盖水、精华、乳液、喷雾、冻干及次抛精华等多种形态。 Q2、公司非贴片类产品占比情况如何？ A：上海研发中心成立后，我们在化妆品产品方面上新速 度持续加快，产品与剂型不断丰富，在产品结构进一步完善的 同时，非贴片类产品的收入占比也在不断提升。 Q3、公司的三类医疗器械产品进展情况如何？ A：目前我们进展比较快的主要是重组Ⅲ型人源化胶原蛋 白冻干纤维、重组Ⅲ型人源化胶原蛋白贴 ...

Core Viewpoint - Fuhua Jia (301371) is a specialized skin care product company focused on the research, production, and sales of professional skin care products, which are divided into medical device products and functional skin care products [1] Group 1: Product Offerings - The company's product forms include masks, waters, serums, lotions, sprays, freeze-dried products, and single-use serums [1] Group 2: Sales Strategy - The company employs an omnichannel strategy for sales, integrating both online and offline channels [1] - Online channels include major e-commerce and social media platforms such as Tmall, Douyin, JD.com, and Pinduoduo [1] - Offline channels penetrate cosmetic specialty stores, large supermarkets, chain pharmacies, beauty institutions, and medical institutions, creating a comprehensive market reach network [1]

《星岛》记者 秦亦 深圳报道 近期，创尔生物（NQ:831187）发布公告，宣布终止北交所上市辅导备案，意味着该公司推进三年之久 的IPO之路正式折戟，一场筹备已久的资本市场冲刺最终未能如愿。 ▲创尔生物终止上市辅导。 创尔生物主要产品为医疗器械类和生物护肤类，在医疗器械方面，该公司已掌握生物医用级活性胶原大 规模无菌提取制备技术，拥有2个Ⅲ类及2个Ⅱ类医疗器械注册证。2017-2019年，公司胶原类产品在我 国医药级胶原市场的市场份额分别为3.04%、3.40%和5.23%。 创尔生物并未在公告中披露股东股权冻结的细节，但据《星岛》了解，这与其二股东丁玉梅有直接关 联。根据创尔生物2025年半年报显示，丁玉梅持有该公司365.36万股，持股比例4.30%，成为第二大股 东。不过，这部分股权已悉数被司法冻结，无任何可流通空间。 事实上，创尔生物的上市之路并非一帆风顺，2020年该公司曾冲击科创板，2021年撤回上市申请材料后 转向北交所，如今却因一桩股权隐患再度停摆。 | | | | | | | | | 期末 | 单位:股 | | --- | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - Chuang'er Bio has officially terminated its IPO preparation after three years of efforts, marking a significant setback in its capital market ambitions [1]. Company Overview - Chuang'er Bio specializes in medical devices and bio-skincare products, having developed large-scale sterile extraction technology for bio-medical grade active collagen, with 2 Class III and 2 Class II medical device registrations [3]. - The company's market share in the pharmaceutical-grade collagen market in China was 3.04% in 2017, 3.40% in 2018, and 5.23% in 2019 [3]. IPO Journey - The company's IPO journey has faced challenges, including an attempt to list on the Sci-Tech Innovation Board in 2020, which was followed by a withdrawal of the application in 2021 and a shift to the Beijing Stock Exchange [4]. - In July 2023, Chuang'er Bio signed a listing guidance agreement with Guotou Securities and submitted the necessary materials to the Guangdong Securities Regulatory Bureau, but the process was halted due to unresolved shareholder equity freeze issues [4]. Shareholder Issues - The termination of the IPO guidance was influenced by a long-standing equity freeze involving the company's second-largest shareholder, Ding Yumei, who holds 365,360 shares (4.30% ownership) that are currently frozen [4][6]. - Ding Yumei's equity freeze is linked to her previous marriage to Xu Jiayin, the former chairman of the now-defunct Evergrande Group, and is part of a broader debt resolution process involving Evergrande [6][7]. Legal and Financial Context - In 2022, Ding Yumei was reported to have reached a "technical divorce" with Xu Jiayin, interpreted as a financial separation to avoid debt liabilities [7]. - Legal actions have been initiated to recover approximately $6 billion in dividends and compensation from Xu Jiayin, Ding Yumei, and other former executives of Evergrande, leading to global asset freezing orders against Ding Yumei [7].

Core Viewpoint - The company, Fulejia, announced on September 23 that its products are primarily divided into two categories: medical devices and functional skincare products, featuring a diverse range of formulations including masks, waters, serums, lotions, sprays, single-use products, and eye masks [2] Group 1 - The company offers a wide variety of product forms, which enhances its market coverage [2] - The product categories include both medical devices and functional skincare, indicating a diversified product portfolio [2]

Group 1: Sales Performance - The company's sales channel optimization has shown significant progress, with a 86.68% increase in revenue from Q1 to Q2 2025, indicating a recovery trend that aligns with company expectations [1] - The lactose acid mask launched in August last year has performed very well in sales during the first half of 2025, meeting company expectations [2] Group 2: Product Structure and Development - The company's product range includes medical devices and functional skincare products, featuring various forms such as masks, essences, lotions, and sprays [1] - The company has a robust pipeline of research projects, with ongoing efforts to enhance R&D capabilities following the establishment of a new R&D center in Shanghai [2] Group 3: Online Sales Channels - JD.com has emerged as a strong online sales channel, with the company enhancing its collaboration with JD to diversify product offerings and implement new promotional strategies, resulting in notable growth on the platform [2] Group 4: Future Plans - The company plans to continue launching new products in the upcoming quarters, with specific details to be announced in future communications [2] - Dividend arrangements for the third quarter are still under consideration, with updates to be provided through official announcements [2]

Core Viewpoint - The company, Fulejia, is experiencing a decline in revenue and net profit for the first half of 2025, but there are signs of recovery in the second quarter due to sales channel optimization and product price adjustments [1][2]. Group 1: Financial Performance - For the first half of 2025, the company reported a revenue of 863 million yuan, a year-on-year decrease of 8.15% [1] - The net profit attributable to shareholders was 230 million yuan, down 32.54% year-on-year [1] - The net profit after excluding non-recurring gains and losses was 166 million yuan, a decrease of 48.66% year-on-year [1] - Basic earnings per share were 0.44 yuan [1] Group 2: Sales Channels and Strategies - The company has implemented a multi-channel sales strategy, integrating online and offline sales, covering major e-commerce platforms like Tmall, Douyin, JD.com, and Pinduoduo, as well as offline medical institutions and retail stores [1] - In the second quarter of 2025, the company saw a significant revenue increase of 86.68% compared to the first quarter, indicating a recovery in performance [2] - The company is focusing on optimizing offline distribution channels, with over 99% of revenue coming from the distribution model, which incurs minimal sales expenses [2] Group 3: Product Development - The company is enhancing its product line, particularly in non-patch products, with a steady increase in their revenue share [3] - The establishment of a research and development center in Shanghai is expected to accelerate product innovation and expansion [3] - The company has completed the third round of injections for a project involving humanized collagen freeze-dried fibers, which is currently in the data cleaning and report preparation stage [3]

Core Insights - The company reported a revenue of 863 million yuan for the first half of 2025, representing a year-on-year decline of 8.15% [1] - The net profit attributable to shareholders was 230 million yuan, down 32.54% year-on-year, with a significant drop in net profit after excluding non-recurring gains and losses to 166 million yuan, a decrease of 48.66% [1] Revenue Breakdown - The average selling price of self-owned brand medical devices increased from 43.52 yuan to 53.37 yuan, but revenue from this category plummeted by 48.07% to 238 million yuan [1] - The average selling price of cosmetics rose from 36.29 yuan to 42.36 yuan, with revenue growth of 29.95% to 625 million yuan, although the gross margin decreased by 1.11 percentage points to 80.42% [1] Channel Performance - Online direct sales generated 536 million yuan, a year-on-year increase of 25.7%, accounting for 62.1% of total revenue, driven by rapid growth through platforms like Tmall and Douyin [1] - Online distribution revenue surged by 246% to 159 million yuan, indicating the company's accelerated expansion into e-commerce distribution networks [1] - Offline channel revenue continued to decline, with distribution income falling by 64.1% to 167 million yuan [1] Expense Analysis - Sales expenses reached 420 million yuan, a significant increase of 39.56% year-on-year, primarily for brand promotion and online traffic investment, with promotional expenses totaling 385 million yuan [2] - Despite the substantial increase in sales expenses, revenue did not see a corresponding rise, indicating pressure on profit margins due to rising customer acquisition costs [2] - The net cash flow from operating activities was 162 million yuan, a decrease of 54.69% year-on-year, mainly due to increased marketing expenditures [2]

Core Viewpoint - The ongoing tariff policies from the U.S. are increasing economic uncertainty and negatively impacting the global pharmaceutical market, prompting Chinese pharmaceutical companies to seek ways to navigate these challenges [1][2]. Group 1: Impact on Chinese Pharmaceutical Industry - In 2024, China's total pharmaceutical import and export volume is projected to reach $199.38 billion, a year-on-year increase of 2.1%, with exports amounting to $107.96 billion, up 5.9%, marking the end of a two-year decline [1]. - The export of traditional Chinese medicine products decreased by 3.3% to $5.28 billion, while exports of Western medicine products increased by 5.7% to $53.96 billion, and medical device exports rose by 7.3% to $48.75 billion [1]. - Chinese pharmaceutical companies primarily focus on the domestic market, with limited export scale to the U.S., and the short-term impact of U.S. tariff policies is expected to be minimal due to temporary exemptions [4]. Group 2: U.S. Pharmaceutical Market Challenges - The U.S. pharmaceutical market is facing significant challenges, with a 25% tariff potentially increasing annual drug costs by $51 billion and raising drug prices by up to 12.9% if costs are fully passed on [3]. - The U.S. is experiencing shortages of hundreds of drugs, including critical emergency medications, due to various factors such as increased prescription volumes and manufacturing delays [3]. - The U.S. heavily relies on imports for 80% of its active pharmaceutical ingredients, making it vulnerable to tariff impacts that could disrupt its medical supply chain [2][3]. Group 3: Strategic Recommendations for Chinese Pharmaceutical Companies - Chinese pharmaceutical companies are advised to enhance their independent research and innovation capabilities to maintain competitiveness amid uncertainties [6]. - Companies should optimize their global presence, focusing on stabilizing markets in Europe and the U.S. while also exploring emerging markets [6]. - There is a need to improve product structures and tap into domestic market growth opportunities, such as those arising from the aging population [6].